The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma

Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution...

Full description

Saved in:
Bibliographic Details
Published inNuclear medicine and molecular imaging Vol. 51; no. 1; pp. 69 - 78
Main Authors Lee, Yeongjoo, Yoo, Ie Ryung, Boo, Sun Ha, Kim, Hyoungwoo, Park, Hye Lim, Hyun O, Joo
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2017
Springer Nature B.V
대한핵의학회
Subjects
Online AccessGet full text
ISSN1869-3474
1869-3482
DOI10.1007/s13139-016-0440-y

Cover

Loading…
Abstract Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p  = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm 3 , and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p  = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p  = 0.020), higher SUVmean (≥3.9, HR: 2.799, p  = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p  = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p  = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p  = 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.
AbstractList Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.
Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imagingmodalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p= 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC. KCI Citation Count: 3
Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). Methods From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. Results The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p  = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm 3 , and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p  = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p  = 0.020), higher SUVmean (≥3.9, HR: 2.799, p  = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p  = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p  = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p  = 0.005). Conclusion FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.
The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC). From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis. The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %,  = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm , and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280,  = 0.001), higher SUVpeak (≥6.5, HR: 2.333,  = 0.020), higher SUVmean (≥3.9, HR: 2.799,  = 0.004), higher SUVgluc (≥8.1, HR: 2.648,  = 0.012), and higher TLGgluc (≥431.6, HR: 2.186,  = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113,  = 0.005). FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.
The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).PURPOSEThe aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma (ICC).From December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.METHODSFrom December 2008 to December 2013, 76 FDG PET/CT scans performed for initial staging of ICC in a single institution (57 male and 19 female; mean age 68 ± 9 years) were retrospectively reviewed. Patients with history of other known malignancy were excluded. Detection rates of regional lymph node and distant metastasis by FDG PET/CT were analyzed in comparison with conventional imaging modalities such as CT or MRI. Metabolic parameters including maximum, peak and mean standardized uptake values (SUVmax, SUVpeak, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), glucose corrected SUV (SUVgluc), and glucose corrected TLG (TLGgluc) were measured for the primary tumor. Cut-off values for the metabolic parameters were calculated by ROC curve analysis, and used to dichotomize the patient groups. The overall survival time (OS) was calculated and compared using the Cox proportional hazard regression analysis.The median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005).RESULTSThe median duration of follow-up period was 5.4 months (interquartile range: 1.45∼15.45). FDG PET/CT showed higher sensitivity than conventional imaging modalities in detection of regional node involvement (74.5 % vs. 61.8 %, p = 0.013). In six patients, distant metastasis was identified only by FDG PET/CT. The mean SUVmax, SUVpeak, SUVmean, MTV, and TLG for the primary tumor were 8.2 ± 3.1, 6.8 ± 2.5, 4.0 ± 0.8, 192.7 ± 360.5 cm3, and 823.7 ± 1615.4, respectively. Patients with higher (≥7.3, HR: 4.280, p = 0.001), higher SUVpeak (≥6.5, HR: 2.333, p = 0.020), higher SUVmean (≥3.9, HR: 2.799, p = 0.004), higher SUVgluc (≥8.1, HR: 2.648, p = 0.012), and higher TLGgluc (≥431.6, HR: 2.186, p = 0.030) showed significantly shorter survival time. By multivariate study, operability was an independent prognostic factor for longer survival (HR: 4.113, p = 0.005).FDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.CONCLUSIONFDG PET/CT is an important diagnostic imaging tool in the nodal staging and detection of distant metastasis in ICC patients. Metabolic parameters may have a significant role as prognostic factors in patients with ICC.
Author Park, Hye Lim
Boo, Sun Ha
Kim, Hyoungwoo
Lee, Yeongjoo
Yoo, Ie Ryung
Hyun O, Joo
Author_xml – sequence: 1
  givenname: Yeongjoo
  surname: Lee
  fullname: Lee, Yeongjoo
  organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 2
  givenname: Ie Ryung
  surname: Yoo
  fullname: Yoo, Ie Ryung
  email: iryoo@catholic.ac.kr
  organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 3
  givenname: Sun Ha
  surname: Boo
  fullname: Boo, Sun Ha
  organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 4
  givenname: Hyoungwoo
  surname: Kim
  fullname: Kim, Hyoungwoo
  organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 5
  givenname: Hye Lim
  surname: Park
  fullname: Park, Hye Lim
  organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 6
  givenname: Joo
  surname: Hyun O
  fullname: Hyun O, Joo
  organization: Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28250860$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002206177$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kUtPGzEUha2KqkDKD-imGqkbWEzxa2zPBilKCURCaoWma8tx7iSGiZ3aE6T8-zoMIEBqvfBD_s7RvfccowMfPCD0heDvBGN5nggjrC4xESXmHJe7D-iIKFGXjCt68HKX_BCdpHSH82K0xkx-QodU0QorgY_QRbOC4jZ0UIS2mJZEFdMfV8Wvy-Z80hTOFzPfR7OCjemdLSar0Bm_dMGaaJ0Pa_MZfWxNl-Dk6Ryh39PLZnJd3vy8mk3GN6WtJO7zDhU2AlpuasOAW5UfEhYLqyRm1XxRG65YzaQRFaVMzVklREVAthwMEMtG6Gzw9bHV99bpYNzjuQz6PurxbTPThHFOJM3sxcButvM1LCzsW-j0Jrq1ibtH5dsf71bZ50FXeaBc8Gxw-mQQw58tpF6vXbLQ5d4hbJMmSjJJeS1URr-9Q-_CNvo8ikwpLIWqs-kIfX1d0UspzzFkQA6AjSGlCK22rs8jD_sCXacJ1vvM9ZC5zpnrfeZ6l5XknfLZ_H8aOmhSZv0S4qui_yn6C_Vuuw0
CitedBy_id crossref_primary_10_1007_s00261_023_03908_y
crossref_primary_10_1016_j_suronc_2020_06_004
crossref_primary_10_1016_j_dld_2020_08_030
crossref_primary_10_1097_MD_0000000000026015
crossref_primary_10_3748_wjg_v25_i11_1289
crossref_primary_10_1007_s00259_017_3779_0
crossref_primary_10_1016_j_suc_2024_06_001
crossref_primary_10_1007_s00261_021_03053_4
crossref_primary_10_3390_diagnostics12112889
crossref_primary_10_1007_s00259_020_05070_9
crossref_primary_10_1002_jgh3_12234
crossref_primary_10_4174_astr_2019_96_4_153
crossref_primary_10_4103_ijnm_ijnm_5_23
crossref_primary_10_1007_s00259_019_04327_2
crossref_primary_10_1097_RLU_0000000000002070
crossref_primary_10_1007_s00259_019_04558_3
crossref_primary_10_3348_kjr_2020_0689
crossref_primary_10_1148_rg_230174
crossref_primary_10_3390_cancers14205151
crossref_primary_10_1007_s00261_021_03183_9
crossref_primary_10_1007_s13139_019_00615_9
crossref_primary_10_3390_cancers15133393
crossref_primary_10_1097_RLU_0000000000002984
crossref_primary_10_1111_liv_15948
crossref_primary_10_7759_cureus_31026
crossref_primary_10_1007_s12094_018_1926_0
crossref_primary_10_1186_s13550_024_01145_y
crossref_primary_10_1007_s12328_022_01712_7
crossref_primary_10_1097_MD_0000000000020932
crossref_primary_10_3390_metabo12040321
crossref_primary_10_1016_j_rcl_2021_06_001
crossref_primary_10_3389_fonc_2021_752036
crossref_primary_10_1186_s40644_020_00323_0
crossref_primary_10_1007_s13193_025_02273_0
crossref_primary_10_1016_j_cpet_2022_03_007
crossref_primary_10_1007_s13139_018_0542_9
crossref_primary_10_1007_s11307_022_01732_2
crossref_primary_10_1007_s00432_018_02832_9
crossref_primary_10_1007_s00261_024_04267_y
crossref_primary_10_1097_RLU_0000000000004641
crossref_primary_10_11569_wcjd_v27_i18_1114
crossref_primary_10_1055_a_1486_3671
crossref_primary_10_1186_s12880_023_01182_4
crossref_primary_10_2967_jnumed_122_265215
crossref_primary_10_1097_RLU_0000000000003055
Cites_doi 10.1016/S0140-6736(05)67530-7
10.1053/jhep.2001.25087
10.1097/00006231-200112000-00002
10.1634/theoncologist.2014-0356
10.1007/s00534-010-0293-1
10.1016/S0002-9610(02)00853-X
10.1053/jhep.2001.23912
10.1097/SLA.0b013e3182a5c985
10.1016/j.jhep.2003.11.030
10.1136/gut.48.6.816
10.1007/s13244-013-0268-2
10.1155/2014/247693
10.1097/RLU.0b013e3182867b99
10.1001/archsurg.2012.1962
10.3350/kjhep.2010.16.3.325
10.1200/JCO.2012.41.5984
10.1007/s00259-003-1297-8
10.1055/s-2004-828889
10.2214/ajr.172.1.9888743
10.1016/j.jhep.2006.03.009
10.1007/s13139-014-0269-1
10.1111/j.1572-0241.2007.01710.x
10.1136/gutjnl-2011-301748
10.1001/jamasurg.2013.5137
10.1200/JCO.2011.35.6519
10.1055/s-2004-828892
10.1007/s00259-002-0852-z
10.1007/s00259-015-3104-8
10.1007/s00330-016-4386-3
10.1186/1470-7330-14-2
ContentType Journal Article
Copyright Korean Society of Nuclear Medicine 2016
Copyright Springer Science & Business Media 2017
Copyright_xml – notice: Korean Society of Nuclear Medicine 2016
– notice: Copyright Springer Science & Business Media 2017
DBID AAYXX
CITATION
NPM
NAPCQ
7X8
5PM
ACYCR
DOI 10.1007/s13139-016-0440-y
DatabaseName CrossRef
PubMed
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList Nursing & Allied Health Premium


PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1869-3482
EndPage 78
ExternalDocumentID oai_kci_go_kr_ARTI_1344172
PMC5313464
28250860
10_1007_s13139_016_0440_y
Genre Journal Article
GroupedDBID ---
-EM
.UV
06D
0R~
0VY
1N0
203
29~
2KG
2VQ
30V
4.4
406
408
40D
67Z
8JR
96X
9ZL
AAAVM
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
AAZMS
ABAKF
ABDZT
ABECU
ABFTV
ABJNI
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHVE
ACKNC
ACMDZ
ACMLO
ACOKC
ACPIV
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGNC
AEJHL
AEJRE
AEMSY
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
AOCGG
AOIJS
ASPBG
AVWKF
AXYYD
AZFZN
BAWUL
BGNMA
CSCUP
DDRTE
DIK
DNIVK
DPUIP
EBLON
EBS
EF.
EIOEI
EJD
ESBYG
F5P
FEDTE
FERAY
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYJPI
GGCAI
GGRSB
GJIRD
GQ6
GQ7
H13
HF~
HMJXF
HRMNR
HVGLF
HYE
HZ~
I0C
IKXTQ
IWAJR
IXD
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O9-
O9J
OK1
P9S
PT4
R9I
RLLFE
ROL
RPM
RSV
S27
S37
S3B
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
T13
TSG
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
Z45
ZMTXR
ZOVNA
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
NPM
ABRTQ
NAPCQ
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c570t-c5e50a6ef4a9a3e4c8a6e7eddc87035bd9a483937a652238b356651e7f4eae1c3
IEDL.DBID AGYKE
ISSN 1869-3474
IngestDate Sun Mar 09 07:51:44 EDT 2025
Thu Aug 21 17:53:37 EDT 2025
Fri Jul 11 08:48:30 EDT 2025
Wed Sep 03 00:23:48 EDT 2025
Wed Feb 19 02:42:55 EST 2025
Tue Jul 01 01:05:50 EDT 2025
Thu Apr 24 23:12:14 EDT 2025
Fri Feb 21 02:35:33 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords SUVmax
Positron-Emission Tomography
Intrahepatic Cholangiocarcinoma
Prognosis
Cholangiocarcinoma
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c570t-c5e50a6ef4a9a3e4c8a6e7eddc87035bd9a483937a652238b356651e7f4eae1c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
G704-SER000001715.2017.51.1.001
OpenAccessLink https://link.springer.com/content/pdf/10.1007/s13139-016-0440-y.pdf
PMID 28250860
PQID 1880768931
PQPubID 2044329
PageCount 10
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_1344172
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5313464
proquest_miscellaneous_1873724968
proquest_journals_1880768931
pubmed_primary_28250860
crossref_citationtrail_10_1007_s13139_016_0440_y
crossref_primary_10_1007_s13139_016_0440_y
springer_journals_10_1007_s13139_016_0440_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-03-01
PublicationDateYYYYMMDD 2017-03-01
PublicationDate_xml – month: 03
  year: 2017
  text: 2017-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Nuclear medicine and molecular imaging
PublicationTitleAbbrev Nucl Med Mol Imaging
PublicationTitleAlternate Nucl Med Mol Imaging
PublicationYear 2017
Publisher Springer Berlin Heidelberg
Springer Nature B.V
대한핵의학회
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
– name: 대한핵의학회
References Kim, Yun, Lee, Kim, Lee (CR24) 2003; 30
Mavros, Economopoulos, Alexiou, Pawlik (CR8) 2014; 149
CR16
Patel (CR6) 2001; 33
CR14
CR33
Feydy, Vilgrain, Denys, Sibert, Belghiti, Vullierme (CR21) 1999; 172
Kluge, Schmidt, Caca, Barthel, Hesse, Georgi (CR22) 2001; 33
Park, Kim, Kim, Jang, Moon, Lee (CR11) 2010; 16
Khan, Thomas, Davidson, Taylor-Robinson (CR1) 2005; 366
Park, Yu, Park, Cheon, Oh, Kim (CR23) 2014; 39
CR30
Taylor-Robinson, Toledano, Arora, Keegan, Hargreaves, Beck (CR4) 2001; 48
Annunziata, Caldarella, Pizzuto, Galiandro, Sadeghi, Giovanella (CR13) 2014; 2014
Albazaz, Patel, Chowdhury, Scarsbrook (CR9) 2013; 4
Kato, Tsukamoto, Kuge, Katoh, Nambu, Nobuta (CR26) 2002; 29
Kawarada, Yamagiwa, Das (CR29) 2002; 183
Khan, Davidson, Goldin, Heaton, Karani, Pereira (CR7) 2012; 61
Shaib, El-Serag (CR2) 2004; 24
Kitamura, Hatano, Higashi, Seo, Nakamoto, Narita (CR31) 2011; 18
Park, Choi, Moon, Yoo, Kim, Ahn (CR34) 2014; 14
Ribero, Pinna, Guglielmi, Ponti, Nuzzo, Giulini (CR18) 2012; 147
Wang, Li, Xia, Gong, Wang, Yan (CR17) 2013; 31
Shaib, Davila, McGlynn, El-Serag (CR5) 2004; 40
Fritscher-Ravens, Bohuslavizki, Broering, Jenicke, Schafer, Buchert (CR27) 2001; 22
Cho, Oh, Kim, Lee, Han, Im (CR32) 2015; 20
Manfredi, Barbaro, Masselli, Vecchioli, Marano (CR15) 2004; 24
Reinhardt, Strunk, Gerhardt, Roedel, Jaeger, Bucerius (CR12) 2005; 46
Jo, Won, Kim, Song, Kang, Kim (CR25) 2014; 48
Petrowsky, Wildbrett, Husarik, Hany, Tam, Jochum (CR28) 2006; 45
Kim, Kim, Lee, Hwang, Kim, Yun (CR10) 2008; 103
Sonbare (CR19) 2014; 259
de Jong, Nathan, Sotiropoulos, Paul, Alexandrescu, Marques (CR20) 2011; 29
Mouzas, Dimoulios, Vlachonikolis, Skordilis, Zoras, Kouroumalis (CR3) 2002; 22
A Fritscher-Ravens (440_CR27) 2001; 22
440_CR14
S Annunziata (440_CR13) 2014; 2014
440_CR16
T Patel (440_CR6) 2001; 33
R Albazaz (440_CR9) 2013; 4
DJ Sonbare (440_CR19) 2014; 259
R Kluge (440_CR22) 2001; 33
SA Khan (440_CR1) 2005; 366
MJ Reinhardt (440_CR12) 2005; 46
MN Mavros (440_CR8) 2014; 149
SK Park (440_CR11) 2010; 16
MC Jong de (440_CR20) 2011; 29
D Ribero (440_CR18) 2012; 147
K Kitamura (440_CR31) 2011; 18
A Feydy (440_CR21) 1999; 172
TG Park (440_CR23) 2014; 39
JY Kim (440_CR10) 2008; 103
Y Wang (440_CR17) 2013; 31
Y Kawarada (440_CR29) 2002; 183
SB Park (440_CR34) 2014; 14
R Manfredi (440_CR15) 2004; 24
H Petrowsky (440_CR28) 2006; 45
IA Mouzas (440_CR3) 2002; 22
YJ Kim (440_CR24) 2003; 30
SD Taylor-Robinson (440_CR4) 2001; 48
Y Shaib (440_CR2) 2004; 24
440_CR33
I Jo (440_CR25) 2014; 48
KM Cho (440_CR32) 2015; 20
YH Shaib (440_CR5) 2004; 40
T Kato (440_CR26) 2002; 29
SA Khan (440_CR7) 2012; 61
440_CR30
11711897 - Nucl Med Commun. 2001 Dec;22(12 ):1277-85
23358969 - J Clin Oncol. 2013 Mar 20;31(9):1188-95
26081941 - Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1984-94
22910846 - Arch Surg. 2012 Dec;147(12):1107-13
9888743 - AJR Am J Roentgenol. 1999 Jan;172(1):73-7
16690156 - J Hepatol. 2006 Jul;45(1):43-50
24955351 - Biomed Res Int. 2014;2014:247693
12095601 - Am J Surg. 2002 Jun;183(6):679-85
15123362 - J Hepatol. 2004 Mar;40(3):472-7
12552969 - Anticancer Res. 2002 Nov-Dec;22(6B):3637-41
25609313 - Cancer Imaging. 2014 Apr 22;14 :2
11343227 - Hepatology. 2001 May;33(5):1029-35
18177454 - Am J Gastroenterol. 2008 May;103(5):1145-51
11358902 - Gut. 2001 Jun;48(6):816-20
26099746 - Oncologist. 2015 Aug;20(8):926-33
24718873 - JAMA Surg. 2014 Jun;149(6):565-74
16000285 - J Nucl Med. 2005 Jul;46(7):1158-63
24335565 - Clin Nucl Med. 2014 Jan;39(1):1-7
20079127 - Chin Med J (Engl). 2009 Oct 5;122(19):2286-91
23979290 - Ann Surg. 2014 Feb;259(2):e36
21730269 - J Clin Oncol. 2011 Aug 10;29(23):3140-5
12173019 - Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54
23884572 - Insights Imaging. 2013 Oct;4(5):691-700
26396641 - Nucl Med Mol Imaging. 2014 Dec;48(4):326-7
27165138 - Eur Radiol. 2017 Feb;27(2):498-506
20924217 - Korean J Hepatol. 2010 Sep;16(3):325-8
15192788 - Semin Liver Dis. 2004 May;24(2):155-64
15192785 - Semin Liver Dis. 2004 May;24(2):115-25
14579085 - Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1467-72
20503059 - J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):39-46
22895392 - Gut. 2012 Dec;61(12 ):1657-69
11391522 - Hepatology. 2001 Jun;33(6):1353-7
16214602 - Lancet. 2005 Oct 8;366(9493):1303-14
References_xml – volume: 366
  start-page: 1303
  issue: 9493
  year: 2005
  end-page: 14
  ident: CR1
  article-title: Cholangiocarcinoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67530-7
– volume: 33
  start-page: 1353
  year: 2001
  end-page: 7
  ident: CR6
  article-title: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States
  publication-title: Hepatology
  doi: 10.1053/jhep.2001.25087
– volume: 22
  start-page: 1277
  year: 2001
  end-page: 85
  ident: CR27
  article-title: FDG PET in the diagnosis of hilar cholangiocarcinoma
  publication-title: Nucl Med Commun
  doi: 10.1097/00006231-200112000-00002
– volume: 20
  start-page: 926
  year: 2015
  end-page: 33
  ident: CR32
  article-title: Metabolic Characteristics of Advanced Biliary Tract Cancer Using F-18-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2014-0356
– ident: CR14
– ident: CR16
– ident: CR30
– volume: 46
  start-page: 1158
  year: 2005
  end-page: 63
  ident: CR12
  article-title: Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies
  publication-title: J Nucl Med
– volume: 18
  start-page: 39
  year: 2011
  end-page: 46
  ident: CR31
  article-title: Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer
  publication-title: J Hepatobiliary Pancreat Sci
  doi: 10.1007/s00534-010-0293-1
– volume: 183
  start-page: 679
  year: 2002
  end-page: 85
  ident: CR29
  article-title: Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma
  publication-title: Am J Surg
  doi: 10.1016/S0002-9610(02)00853-X
– volume: 33
  start-page: 1029
  year: 2001
  end-page: 35
  ident: CR22
  article-title: Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer
  publication-title: Hepatology
  doi: 10.1053/jhep.2001.23912
– ident: CR33
– volume: 259
  start-page: e36
  year: 2014
  ident: CR19
  article-title: Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 Study Group
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e3182a5c985
– volume: 40
  start-page: 472
  year: 2004
  end-page: 7
  ident: CR5
  article-title: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2003.11.030
– volume: 48
  start-page: 816
  year: 2001
  end-page: 20
  ident: CR4
  article-title: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998
  publication-title: Gut
  doi: 10.1136/gut.48.6.816
– volume: 4
  start-page: 691
  year: 2013
  end-page: 700
  ident: CR9
  article-title: Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours
  publication-title: Insights Imaging
  doi: 10.1007/s13244-013-0268-2
– volume: 22
  start-page: 3637
  year: 2002
  end-page: 41
  ident: CR3
  article-title: Increasing incidence of cholangiocarcinoma in Crete 1992-2000
  publication-title: Anticancer Res
– volume: 2014
  start-page: 247693
  year: 2014
  ident: CR13
  article-title: Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis
  publication-title: Biomed Res Int
  doi: 10.1155/2014/247693
– volume: 39
  start-page: 1
  year: 2014
  end-page: 7
  ident: CR23
  article-title: Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0b013e3182867b99
– volume: 147
  start-page: 1107
  year: 2012
  end-page: 13
  ident: CR18
  article-title: Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients
  publication-title: Arch Surg
  doi: 10.1001/archsurg.2012.1962
– volume: 16
  start-page: 325
  year: 2010
  end-page: 8
  ident: CR11
  article-title: Detection of distant metastasis to skeletal muscle by 18F-FDG-PET in a case of intrahepatic cholangiocarcinoma
  publication-title: Korean J Hepatol
  doi: 10.3350/kjhep.2010.16.3.325
– volume: 31
  start-page: 1188
  year: 2013
  end-page: 95
  ident: CR17
  article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.5984
– volume: 30
  start-page: 1467
  year: 2003
  end-page: 72
  ident: CR24
  article-title: Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-003-1297-8
– volume: 24
  start-page: 115
  year: 2004
  end-page: 25
  ident: CR2
  article-title: The epidemiology of cholangiocarcinoma
  publication-title: Semin Liver Dis
  doi: 10.1055/s-2004-828889
– volume: 172
  start-page: 73
  year: 1999
  end-page: 7
  ident: CR21
  article-title: Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/ajr.172.1.9888743
– volume: 45
  start-page: 43
  year: 2006
  end-page: 50
  ident: CR28
  article-title: Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.03.009
– volume: 48
  start-page: 326
  year: 2014
  end-page: 7
  ident: CR25
  article-title: Catheter Tract Implantation Metastasis Diagnosed by F-18 FDG PET/CT After Percutaneous Transhepatic Biliary Drainage for Hilar Cholangiocarcinoma
  publication-title: Nucl Med Mol Imaging
  doi: 10.1007/s13139-014-0269-1
– volume: 103
  start-page: 1145
  year: 2008
  end-page: 51
  ident: CR10
  article-title: Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2007.01710.x
– volume: 61
  start-page: 1657
  issue: 12
  year: 2012
  end-page: 69
  ident: CR7
  article-title: Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
  publication-title: Gut
  doi: 10.1136/gutjnl-2011-301748
– volume: 149
  start-page: 565
  issue: 6
  year: 2014
  end-page: 574
  ident: CR8
  article-title: Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis
  publication-title: JAMA Surg.
  doi: 10.1001/jamasurg.2013.5137
– volume: 29
  start-page: 3140
  year: 2011
  end-page: 5
  ident: CR20
  article-title: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.6519
– volume: 14
  start-page: 2
  year: 2014
  ident: CR34
  article-title: Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer
  publication-title: Cancer Imaging
– volume: 24
  start-page: 155
  year: 2004
  end-page: 64
  ident: CR15
  article-title: Magnetic resonance imaging of cholangiocarcinoma
  publication-title: Semin Liver Dis
  doi: 10.1055/s-2004-828892
– volume: 29
  start-page: 1047
  year: 2002
  end-page: 54
  ident: CR26
  article-title: Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-002-0852-z
– ident: 440_CR16
– volume: 31
  start-page: 1188
  year: 2013
  ident: 440_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.5984
– volume: 29
  start-page: 1047
  year: 2002
  ident: 440_CR26
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-002-0852-z
– volume: 45
  start-page: 43
  year: 2006
  ident: 440_CR28
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.03.009
– volume: 4
  start-page: 691
  year: 2013
  ident: 440_CR9
  publication-title: Insights Imaging
  doi: 10.1007/s13244-013-0268-2
– volume: 46
  start-page: 1158
  year: 2005
  ident: 440_CR12
  publication-title: J Nucl Med
– volume: 39
  start-page: 1
  year: 2014
  ident: 440_CR23
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0b013e3182867b99
– volume: 33
  start-page: 1029
  year: 2001
  ident: 440_CR22
  publication-title: Hepatology
  doi: 10.1053/jhep.2001.23912
– volume: 22
  start-page: 3637
  year: 2002
  ident: 440_CR3
  publication-title: Anticancer Res
– volume: 18
  start-page: 39
  year: 2011
  ident: 440_CR31
  publication-title: J Hepatobiliary Pancreat Sci
  doi: 10.1007/s00534-010-0293-1
– volume: 16
  start-page: 325
  year: 2010
  ident: 440_CR11
  publication-title: Korean J Hepatol
  doi: 10.3350/kjhep.2010.16.3.325
– volume: 30
  start-page: 1467
  year: 2003
  ident: 440_CR24
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-003-1297-8
– volume: 366
  start-page: 1303
  issue: 9493
  year: 2005
  ident: 440_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67530-7
– volume: 149
  start-page: 565
  issue: 6
  year: 2014
  ident: 440_CR8
  publication-title: JAMA Surg.
  doi: 10.1001/jamasurg.2013.5137
– volume: 183
  start-page: 679
  year: 2002
  ident: 440_CR29
  publication-title: Am J Surg
  doi: 10.1016/S0002-9610(02)00853-X
– volume: 48
  start-page: 816
  year: 2001
  ident: 440_CR4
  publication-title: Gut
  doi: 10.1136/gut.48.6.816
– ident: 440_CR33
  doi: 10.1007/s00259-015-3104-8
– volume: 103
  start-page: 1145
  year: 2008
  ident: 440_CR10
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2007.01710.x
– volume: 29
  start-page: 3140
  year: 2011
  ident: 440_CR20
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.6519
– volume: 24
  start-page: 115
  year: 2004
  ident: 440_CR2
  publication-title: Semin Liver Dis
  doi: 10.1055/s-2004-828889
– volume: 24
  start-page: 155
  year: 2004
  ident: 440_CR15
  publication-title: Semin Liver Dis
  doi: 10.1055/s-2004-828892
– volume: 40
  start-page: 472
  year: 2004
  ident: 440_CR5
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2003.11.030
– volume: 172
  start-page: 73
  year: 1999
  ident: 440_CR21
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/ajr.172.1.9888743
– volume: 2014
  start-page: 247693
  year: 2014
  ident: 440_CR13
  publication-title: Biomed Res Int
  doi: 10.1155/2014/247693
– volume: 48
  start-page: 326
  year: 2014
  ident: 440_CR25
  publication-title: Nucl Med Mol Imaging
  doi: 10.1007/s13139-014-0269-1
– volume: 33
  start-page: 1353
  year: 2001
  ident: 440_CR6
  publication-title: Hepatology
  doi: 10.1053/jhep.2001.25087
– ident: 440_CR14
  doi: 10.1007/s00330-016-4386-3
– volume: 61
  start-page: 1657
  issue: 12
  year: 2012
  ident: 440_CR7
  publication-title: Gut
  doi: 10.1136/gutjnl-2011-301748
– ident: 440_CR30
– volume: 259
  start-page: e36
  year: 2014
  ident: 440_CR19
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e3182a5c985
– volume: 14
  start-page: 2
  year: 2014
  ident: 440_CR34
  publication-title: Cancer Imaging
  doi: 10.1186/1470-7330-14-2
– volume: 22
  start-page: 1277
  year: 2001
  ident: 440_CR27
  publication-title: Nucl Med Commun
  doi: 10.1097/00006231-200112000-00002
– volume: 20
  start-page: 926
  year: 2015
  ident: 440_CR32
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2014-0356
– volume: 147
  start-page: 1107
  year: 2012
  ident: 440_CR18
  publication-title: Arch Surg
  doi: 10.1001/archsurg.2012.1962
– reference: 27165138 - Eur Radiol. 2017 Feb;27(2):498-506
– reference: 15192785 - Semin Liver Dis. 2004 May;24(2):115-25
– reference: 23358969 - J Clin Oncol. 2013 Mar 20;31(9):1188-95
– reference: 14579085 - Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1467-72
– reference: 23979290 - Ann Surg. 2014 Feb;259(2):e36
– reference: 11343227 - Hepatology. 2001 May;33(5):1029-35
– reference: 23884572 - Insights Imaging. 2013 Oct;4(5):691-700
– reference: 11358902 - Gut. 2001 Jun;48(6):816-20
– reference: 24955351 - Biomed Res Int. 2014;2014:247693
– reference: 9888743 - AJR Am J Roentgenol. 1999 Jan;172(1):73-7
– reference: 12552969 - Anticancer Res. 2002 Nov-Dec;22(6B):3637-41
– reference: 24718873 - JAMA Surg. 2014 Jun;149(6):565-74
– reference: 26099746 - Oncologist. 2015 Aug;20(8):926-33
– reference: 11391522 - Hepatology. 2001 Jun;33(6):1353-7
– reference: 16214602 - Lancet. 2005 Oct 8;366(9493):1303-14
– reference: 18177454 - Am J Gastroenterol. 2008 May;103(5):1145-51
– reference: 16690156 - J Hepatol. 2006 Jul;45(1):43-50
– reference: 25609313 - Cancer Imaging. 2014 Apr 22;14 :2
– reference: 15123362 - J Hepatol. 2004 Mar;40(3):472-7
– reference: 20079127 - Chin Med J (Engl). 2009 Oct 5;122(19):2286-91
– reference: 21730269 - J Clin Oncol. 2011 Aug 10;29(23):3140-5
– reference: 15192788 - Semin Liver Dis. 2004 May;24(2):155-64
– reference: 12095601 - Am J Surg. 2002 Jun;183(6):679-85
– reference: 12173019 - Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54
– reference: 22910846 - Arch Surg. 2012 Dec;147(12):1107-13
– reference: 20924217 - Korean J Hepatol. 2010 Sep;16(3):325-8
– reference: 26396641 - Nucl Med Mol Imaging. 2014 Dec;48(4):326-7
– reference: 26081941 - Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1984-94
– reference: 11711897 - Nucl Med Commun. 2001 Dec;22(12 ):1277-85
– reference: 16000285 - J Nucl Med. 2005 Jul;46(7):1158-63
– reference: 24335565 - Clin Nucl Med. 2014 Jan;39(1):1-7
– reference: 20503059 - J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):39-46
– reference: 22895392 - Gut. 2012 Dec;61(12 ):1657-69
SSID ssj0000329037
Score 2.2702737
Snippet Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic...
The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic cholangiocarcinoma...
Purpose The aim of this study was to evaluate the diagnostic and prognostic role of metabolic parameters of FDG PET/CT in patients with intrahepatic...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 69
SubjectTerms Cardiology
Computed tomography
Diagnostic software
Diagnostic systems
Fluorine
Glucose
Glycolysis
Imaging
Magnetic resonance imaging
Mathematical analysis
Medical prognosis
Medicine
Medicine & Public Health
Metabolism
Metastasis
Nuclear Medicine
Oncology
Original
Original Article
Orthopedics
Patients
Positron emission
Radioisotopes
Radiology
Regional analysis
Regression analysis
Survival
Tomography
방사선과학
Title The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma
URI https://link.springer.com/article/10.1007/s13139-016-0440-y
https://www.ncbi.nlm.nih.gov/pubmed/28250860
https://www.proquest.com/docview/1880768931
https://www.proquest.com/docview/1873724968
https://pubmed.ncbi.nlm.nih.gov/PMC5313464
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002206177
Volume 51
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Nuclear Medicine and Molecular Imaging , 2017, 51(1), , pp.69-78
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED_RTkK8AOMzsFUG8QTKlsRO4rwgdd2yDbQJoVYaT5bjOFvVkaCufRh_PXdp0q5jIO0lUeRzZPvu4rvc-XcAH3w_k1FhcldEUriCZ7FLVohrUJgDsufDiA4nn5xGRyPx5Sw8a85xX7XZ7m1Isv5Srw67cbRW0PVFD5gCktcd2Ah9mcgubPQPf3xd_VrxeJB4NVom1VtyuYhFG8-86z1rO1KnnBZ3GZt_50zeCpzW-1H6BIbtTBZpKJOd-SzbMb9vgTzec6pP4XFjn7L-QqA24YEtn8HDkyYC_xw-o1yx79WlZVXBUteXLN0_ZN8OhruDIRuX7JjGfWEpT9uwATnO5fkY98spdq9-6hcwSg-GgyO3qcHgmjD2Zni1oacjWwidaG6FkfgQ2zw3qOg8zPJEC0mgejpCS47LDJkbhb6NC2G19Q1_Cd2yKu1rYHmIvp1NtGcIVy2zMvd4IXLtxUXI40I64LV8UKYBKKc6GZdqBa1M66IoKY3WRV078HHZ5dcCneN_xO-RuWpixoowtel-XqnJVKHncKx8TsXYAge2Wt6rRpuvFGHWoVuWcN-Bd8tm1EMKrujSVnOioYI_IolwHq8WorIcEp0PRtfRcyBeE6IlAY1nvaUcX9RY3_iJ5CISDnxqJeXGsP410zf3on4LjwKyVerEui3ozqZzu42W1izroWale3unvUbDetAZBf0_k_UdpQ
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-xIQEvaHwHNjCIJ1A0J3Yc5wVp6lZaWCeEWmlvluM4W7WRoK572H_PXZpklA0kXhJFthPb54_f5c6_A3gfRblWpStCqbQMpcjTkFBI6HAwx4TnE0WHkydHajSTX46T4_Yc90Xn7d6ZJJuV-vqwm0C0gqovasBkkLzagLuIBTSFLZjFe_2PFS7ijDdcmRRtKRQylZ0187a3rO1HG9WivA1q3vSY_MNs2uxGwy142MJItreS-yO446vHcG_SGsqfwCcUP_ten3tWl2wYRpoN9z-zbwfT3cGUzSs2pg-cenKndmxA-m11MsdtbYHF6x_2KcyGB9PBKGxDJYQuSfkSrz7hVvlS2swKL53Gh9QXhcP5KJK8yKzUxH1nFQIuoXOUgUoin5bSWx858Qw2q7ryL4AVCapgPrPcEf1Z7nXBRSkLy9MyEWmpA-BdhxnX8ohTOItzc82ATH1syHeM-thcBfChL_JzRaLxr8zvUArmzM0NUV_T_aQ2ZwuDAH9sIkEx0-IAtjshmXbSXRiilkPtKRNRAG_7ZJwuZAOxla8vKQ_F5ZGZwnY8X8m0rxId40UNjweQrkm7z0D1WU-p5qcNJTeuZEIqGcDHblz8Vq2_tfTlf-V-A_dH08mhORwffX0FD2KCF40v3DZsLheXfgfB0TJ_3UyGX9VNAR0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB3RIlVcEN8EChjECRRtEjtOckGqtg1doFWFdqXeLMex21WLU223h_57ZrJJykJB4pIosZM4nnH8JjN-A_A-jqtcOlOHQuYiFLzKQkIhoUFlTgjPp5IWJx8cyv2Z-HKcHnd5Ti_7aPfeJbla00AsTX45uqjd6GbhG0fkgmYwWsPknLzegLuCzqFCz5Kd4SdLxJMiankzKfNSyEUmes_mbXdZm5s2_MLdBjv_jJ78zYXazkzlA7jfQUq2s9KBh3DH-kewddA5zR_DJ1QF9r05t6xxrAzjnJW7n9nR3nQ0nrK5ZxN6wKml0GrDxmTr-pM5TnELvLz5oZ_ArNybjvfDLm1CaNIsWuLWppGW1gldaG6FyfEgs3VtcGzytKoLLXLiwdMSwRfPK5SHTGObOWG1jQ1_Cpu-8fY5sDpFc8wWOjJEhVbZvI64E7WOMpfyzOUBRH2HKdNxilNqi3N1w4ZMfawojoz6WF0H8GG45GJFqPGvyu9QCurMzBXRYNP-pFFnC4Vgf6JiTvnTkgC2eyGpbgBeKqKZQ0uq4HEAb4diHDrkD9HeNldUh3L0iELiezxbyXRoEi3pRWsvCiBbk_ZQgdqzXuLnpy09N37VuJAigI-9XvzSrL-96Yv_qv0Gto52S_Vtcvj1JdxLCGm0YXHbsLlcXNlXiJOW1et2LPwEpT4FWQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Role+of+F-18+FDG+PET%2FCT+in+Intrahepatic+Cholangiocarcinoma&rft.jtitle=Nuclear+medicine+and+molecular+imaging&rft.au=Lee%2C+Yeongjoo&rft.au=Yoo%2C+Ie+Ryung&rft.au=Boo%2C+Sun+Ha&rft.au=Kim%2C+Hyoungwoo&rft.date=2017-03-01&rft.issn=1869-3474&rft.volume=51&rft.issue=1&rft.spage=69&rft_id=info:doi/10.1007%2Fs13139-016-0440-y&rft_id=info%3Apmid%2F28250860&rft.externalDocID=28250860
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1869-3474&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1869-3474&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1869-3474&client=summon